科研之友
微信
新浪微博
Facebook
分享链接
摘要
The purpose of this study was to evaluate the efficacy and safety of lacidipine tablets to treating Chinese patients with mild to moderate essential hypertension. We systematically searched the Cochrane central register of controlled trials (Issue 2, 2011), Medline (1966 to June 2011), EMbase (1966 to June 2011), CNKI (1993 to June 2011), WANFANG (1981 to June 2011), VIP (1989 to June 2011) and CBM (1991 to June 2011) through the computer and manually retrieved the relevant literature with pre-specified criteria. Then, we evaluated the quality of selected articles, extracted data and used Revman 5.1 software to do a meta-analysis. A total of 819 articles were found and 13 articles finally included were all randomized clinical trials that examined the efficacy and safety of using lacidipine tablets to treat mild to moderate essential hypertension among Chinese people. For the heterogeneity test, the efficacy analysis (Q statistic = 12.02, I-2 = 0%, Z = 3.43, P = 0.0006) and safety analysis (Q statistic = 15.77, p = 0.20, I-2 = 24%, Z = 3.58, P = 0.0003) showed that lacidipine was more effective and safer than other currently available antihypertensive agents. Meta-analysis showed that there was a significant difference between the total efficiency and adverse effect of lacidipine and other antihypertensive drugs. The evidence currently available shows that lacidipine tablets have a better efficacy and safety compared with other active antihypertensive agents used to treat mild to moderate essential hypertension.
- 出版日期2012-8
- 单位吉林大学
